MedTrace Logo

A Study of Orally Administered IPG7236 in Healthy Adult Participants

NCT05288543 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2025-12-22

No results posted yet for this study

Summary

The study is a phase 1, randomized, double-blind, placebo-controlled, single and multiple dose escalation study to evaluate the safety, tolerability, pharmacokinetic and food effect of orally administered IPG7236 in healthy adult participants.

Conditions

Interventions

DRUG

IPG7236- Single ascending dose

Subjects will receive IPG7236 tablets orally once on Day 1 in a fasted state

DRUG

IPG7236- Multiple ascending dose

Subjects will receive IPG7236 tablets orally once daily for 10 days from Day1 to Day 10 in a fasted state

OTHER

Placebo (Part A)

Subjects will receive IPG7236 tablets orally once on Day 1 (Part A) or once daily for 10 days from Day1 to Day 10 (Part B) in a fasted state

Sponsors & Collaborators

  • Novotech (Australia) Pty Limited

    collaborator INDUSTRY

  • Nanjing Immunophage Biotech Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-07
Primary Completion
2023-03-31
Completion
2025-11-26

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05288543 on ClinicalTrials.gov